Cargando…

An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer

PURPOSE: The purpose of this study was to evaluate the combined measurement of serum CEA, TPA, and CA 15-3, using an individual reference limit (IRL), for predicting distant metastases in asymptomatic women following a diagnosis of primary breast cancer. METHODS: A total of 231 patients were followe...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolini, Andrea, Carpi, Angelo, Ferrari, Paola, Morganti, Riccardo, Mazzotti, Valentina, Barak, Vivian, Duffy, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300365/
https://www.ncbi.nlm.nih.gov/pubmed/30588093
http://dx.doi.org/10.2147/CMAR.S177522
_version_ 1783381665580580864
author Nicolini, Andrea
Carpi, Angelo
Ferrari, Paola
Morganti, Riccardo
Mazzotti, Valentina
Barak, Vivian
Duffy, Michael J
author_facet Nicolini, Andrea
Carpi, Angelo
Ferrari, Paola
Morganti, Riccardo
Mazzotti, Valentina
Barak, Vivian
Duffy, Michael J
author_sort Nicolini, Andrea
collection PubMed
description PURPOSE: The purpose of this study was to evaluate the combined measurement of serum CEA, TPA, and CA 15-3, using an individual reference limit (IRL), for predicting distant metastases in asymptomatic women following a diagnosis of primary breast cancer. METHODS: A total of 231 patients were followed up for a mean of 5.5±1.6 years. An IRL for defining critical changes (CCs) in marker levels was used as a warning signal of pending distant metastases. RESULTS: Sensitivity, specificity, and accuracy of the combined CEA–TPA–CA 15-3 marker panel for predicting patient outcome were 95.2%, 97.8%, and 97.9%, respectively. In all, 19 (8.3%) patients relapsed with a mean lead time to radiological evidence of metastases of 11.7±13.8 months. CONCLUSION: We concluded that the combined measurement of CA 15-3, CEA, and TPA using an IRL for determining the CC in markers levels is an accurate strategy for predicting outcome during postoperative monitoring of asymptomatic breast cancer patients. Whether the early prediction of metastasis and subsequent administration of therapy impacts on patient outcome should now be the objective of a prospective clinical trial. The marker panel described here could serve as the basis for such a trial.
format Online
Article
Text
id pubmed-6300365
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63003652018-12-26 An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer Nicolini, Andrea Carpi, Angelo Ferrari, Paola Morganti, Riccardo Mazzotti, Valentina Barak, Vivian Duffy, Michael J Cancer Manag Res Original Research PURPOSE: The purpose of this study was to evaluate the combined measurement of serum CEA, TPA, and CA 15-3, using an individual reference limit (IRL), for predicting distant metastases in asymptomatic women following a diagnosis of primary breast cancer. METHODS: A total of 231 patients were followed up for a mean of 5.5±1.6 years. An IRL for defining critical changes (CCs) in marker levels was used as a warning signal of pending distant metastases. RESULTS: Sensitivity, specificity, and accuracy of the combined CEA–TPA–CA 15-3 marker panel for predicting patient outcome were 95.2%, 97.8%, and 97.9%, respectively. In all, 19 (8.3%) patients relapsed with a mean lead time to radiological evidence of metastases of 11.7±13.8 months. CONCLUSION: We concluded that the combined measurement of CA 15-3, CEA, and TPA using an IRL for determining the CC in markers levels is an accurate strategy for predicting outcome during postoperative monitoring of asymptomatic breast cancer patients. Whether the early prediction of metastasis and subsequent administration of therapy impacts on patient outcome should now be the objective of a prospective clinical trial. The marker panel described here could serve as the basis for such a trial. Dove Medical Press 2018-12-13 /pmc/articles/PMC6300365/ /pubmed/30588093 http://dx.doi.org/10.2147/CMAR.S177522 Text en © 2018 Nicolini et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Nicolini, Andrea
Carpi, Angelo
Ferrari, Paola
Morganti, Riccardo
Mazzotti, Valentina
Barak, Vivian
Duffy, Michael J
An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
title An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
title_full An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
title_fullStr An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
title_full_unstemmed An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
title_short An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
title_sort individual reference limit of the serum cea–tpa–ca 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300365/
https://www.ncbi.nlm.nih.gov/pubmed/30588093
http://dx.doi.org/10.2147/CMAR.S177522
work_keys_str_mv AT nicoliniandrea anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT carpiangelo anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT ferraripaola anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT morgantiriccardo anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT mazzottivalentina anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT barakvivian anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT duffymichaelj anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT nicoliniandrea individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT carpiangelo individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT ferraripaola individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT morgantiriccardo individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT mazzottivalentina individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT barakvivian individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer
AT duffymichaelj individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer